Precision Neuroscience Corporation (Precision) today announced a strategic partnership with Medtronic to advance neurosurgery, leveraging Precision’s brain–computer interface (BCI) technology and ...

Glo & Spa-rkle Aesthetics and Medical Spa, a leading name in aesthetic and wellness services, is thrilled to announce its relocation to a brand new, state-of-the-art facility in Lubbock, Texas. The ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

The preliminary, unaudited revenue results and cash, cash equivalents and financial assets described in this press release are estimates only and are subject to revision until Nyxoah reports its full ...

A live webcast of the fireside chat can be found here and on the investor relations section of the Company’s website at https://investors.genelux.com/. Following the live webcast, an archived replay ...

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that ...

- Rapid increase in diagnosis of ADH1 with >1,700 unique patients identified since October 2023; BridgeBio intends to submit an NDA to the FDA based on results from CALIBRATE, the Company’s Phase 3 ...

New York, USA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sorevna, a company in the cosmetics industry, today announced its planned entry into the bath and body care segment, expanding its existing product ...

“2025 was a transformational year for SafeSpace Global, and our operational momentum remains exceptionally strong,” said Scott M. Boruff, Chief Executive Officer. “We are entering 2026 with the ...

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA 1 ...

SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- JP Morgan Healthcare Conference -- Nudj Health, the leading AI-powered whole-person, lifestyle-medicine care enablement company, today announced that ...

KaiNETIC-3: target enrollment of 1,200 adults with a BMI of 35 kg/m 2 or greater and without type 2 diabetes. This trial will include an arm that will be randomized to open-label semaglutide 2.4 mg ...